ergocristine

ID: ALA446315

Chembl Id: CHEMBL446315

Cas Number: 511-08-0

PubChem CID: 31116

Max Phase: Preclinical

Molecular Formula: C35H39N5O5

Molecular Weight: 609.73

Molecule Type: Small molecule

Names and Identifiers

Synonyms: Ergocristine | Ergocristine|511-08-0|Ergocrystine|MLS000069350|3E58HO2T0U|CHEBI:4821|SMR000058447|Ergotaman-3',6',18-trione,12'-hydroxy-2'-(1-methylethyl)-5'-(phenylmethyl)-, (5'a)-|Ergocristin|(6aR,9R)-N-[(1S,2S,4R,7S)-7-benzyl-2-hydroxy-5,8-dioxo-4-propan-2-yl-3-oxa-6,9-diazatricyclo[7.3.0.02,6]dodecan-4-yl]-7-methyl-6,6a,8,9-tetrahydro-4H-indolo[4,3-fg]quinoline-9-carboxamide|5'alpha-benzyl-12'-hydroxy-3',6',18-trioxo-2'-(propan-2-yl)ergotaman|NSC 93743|UNII-3E58HO2T0U|NSC-93743|12'-hydroxy-2Show More⌵

Canonical SMILES:  CC(C)[C@@]1(NC(=O)[C@@H]2C=C3c4cccc5[nH]cc(c45)C[C@H]3N(C)C2)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](Cc3ccccc3)N2C1=O

Standard InChI:  InChI=1S/C35H39N5O5/c1-20(2)34(37-31(41)23-16-25-24-11-7-12-26-30(24)22(18-36-26)17-27(25)38(3)19-23)33(43)40-28(15-21-9-5-4-6-10-21)32(42)39-14-8-13-29(39)35(40,44)45-34/h4-7,9-12,16,18,20,23,27-29,36,44H,8,13-15,17,19H2,1-3H3,(H,37,41)/t23-,27-,28+,29+,34-,35+/m1/s1

Standard InChI Key:  HEFIYUQVAZFDEE-MKTPKCENSA-N

Alternative Forms

1. Parent:

   

   ALA446315

   ERGOCRISTINE

Molecule Features

Natural Product: Yes

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 609.73

Molecular Weight (Monoisotopic): 609.2951

AlogP: 2.63

#Rotatable Bonds: 5

Polar Surface Area: 118.21

Molecular Species: NEUTRAL

HBA: 6

HBD: 3

#RO5 Violations: 1

HBA (Lipinski): 10

HBD (Lipinski): 3

#RO5 Violations (Lipinski): 1

CX Acidic pKa: 9.69

CX Basic pKa: 7.78

CX LogP: 3.71

CX LogD: 3.28

Aromatic Rings: 3

Heavy Atoms: 45

QED Weighted: 0.41

Np Likeness Score: 1.17

References

1. Pedersen JM, Matsson P, Bergström CA, Norinder U, Hoogstraate J, Artursson P..  (2008)  Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,  51  (11): [PMID:18457386] [10.1021/jm7015683]

2. Diamandis P, Wildenhain J, Clarke ID, Sacher AG, Graham J, Bellows DS, Ling EK, Ward RJ, Jamieson LG, Tyers M, Dirks PB..  (2007)  Chemical genetics reveals a complex functional ground state of neural stem cells.,  3  (5): [PMID:17417631] [10.1038/nchembio873]

3. PubChem BioAssay data set, 

4. Yasuda K, Lan LB, Sanglard D, Furuya K, Schuetz JD, Schuetz EG..  (2002)  Interaction of cytochrome P450 3A inhibitors with P-glycoprotein.,  303  (1): [PMID:12235267] [10.1124/jpet.102.037549]

5. Ekins S, Kim RB, Leake BF, Dantzig AH, Schuetz EG, Lan LB, Yasuda K, Shepard RL, Winter MA, Schuetz JD, Wikel JH, Wrighton SA..  (2002)  Three-dimensional quantitative structure-activity relationships of inhibitors of P-glycoprotein.,  61  (1): [PMID:11961113] [10.1124/mol.61.5.964]

Source

Source(3):

• Scientific Literature
• PubChem BioAssays
• TP-search Transporter Database